Ducrotté P
ADEN EA 4311/IFRMP 23, Department of Hepatogastroenterology and Nutrition, Regional University Hospital, Charles Nicolle Hospital, 1 Rue de Germont, Rouen Cedex, France.
Gastroenterol Clin Biol. 2010 Sep;34 Suppl 1:S52-6. doi: 10.1016/S0399-8320(10)70021-X.
Irritable bowel syndrome (IBS) is a multifactorial disease during which the pathophysiological role of the gut microbiota has been recently highlighted. In almost 20% of the patients, IBS is clearly a post-infectious IBS as a consequence of an acute bacterial gastroenteritis. Some papers have reported an abnormal colonic fermentation in IBS patients that could explain symptoms such as bloating and be one of the factors triggering visceral hypersensitivity. More recently, significant differences in the composition of both the luminal and mucosa-associated microbiota have been reported between both IBS patients and healthy controls and IBS subgroups while some arguments exist for a small intestinal overgrowth in a subset of IBS patients. All these arguments for a deleterious role of the gut microbiota lead to the actual discuss to consider new therapeutic options, including mainly pre- and probiotics and maybe antibiotics.
肠易激综合征(IBS)是一种多因素疾病,近年来肠道微生物群的病理生理作用受到了关注。在近20%的患者中,IBS显然是急性细菌性肠胃炎导致的感染后IBS。一些论文报道,IBS患者存在异常的结肠发酵,这可以解释腹胀等症状,并且是引发内脏高敏感性的因素之一。最近,有报道称IBS患者与健康对照以及IBS亚组之间,管腔和黏膜相关微生物群的组成存在显著差异,同时有证据表明一部分IBS患者存在小肠细菌过度生长。所有这些关于肠道微生物群有害作用的观点引发了当前对于新治疗选择的讨论,主要包括益生元和益生菌,可能还包括抗生素。